Oral morphine pharmacokinetic in obesity: the role of P-glycoprotein, MRP2, MRP3, UGT2B7 and CYP3A4 jejunal contents and obesity-associated biomarkers.
In Mol Pharm, Feb 2016
OBJECTIVE: To study the influence of the jejunal expression levels of P-gp, MRP2, MRP3, UGT2B7, CYP3A4, the influence of the ABCB1 c.3435C>T polymorphism and of several obesity-associated biomarkers, on oral morphine and glucuronides pharmacokinetics in a population of morbid obese subjects.
Characterization of 137 Genomic DNA Reference Materials for 28 Pharmacogenetic Genes: A GeT-RM Collaborative Project.
Camden, United States. In J Mol Diagn, Jan 2016
To address this need, the Centers for Disease Control and Prevention-based Genetic Testing Reference Material Coordination Program, in collaboration with members of the pharmacogenetic testing community and the Coriell Cell Repositories, has characterized 137 genomic DNA samples for 28 genes commonly genotyped by pharmacogenetic testing assays (CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A5, CYP4F2, DPYD, GSTM1, GSTP1, GSTT1, NAT1, NAT2, SLC15A2, SLC22A2, SLCO1B1, SLCO2B1, TPMT, UGT1A1, UGT2B7, UGT2B15, UGT2B17, and VKORC1).
Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update.
Brisbane, Australia. In Arch Toxicol, 2014
Genetic variants within genes involved in MPA metabolism (UGT1A9, UGT1A8, UGT2B7), cellular transportation (SLCOB1, SLCO1B3, ABCC2) and targets (IMPDH) have been reported to effect MPA pharmacokinetics and/or response in some studies; however, larger studies across different ethnic groups that take into account genetic linkage and drug interactions that can alter a patient's phenotype are needed before any clinical recommendations based on patient genotype can be formulated.
Genetic basis of drug-induced liver injury: present and future.
Newcastle upon Tyne, United Kingdom. In Semin Liver Dis, 2014
Though the associations with non-HLA genes have been less well replicated than the HLA associations, there is increasing evidence that drug metabolism genes such as NAT2 and UGT2B7 contribute to some forms of DILI.
Pharmacogenetic potential biomarkers for carbamazepine adverse drug reactions and clinical response.
In Drug Metabol Drug Interact, 2013
On the other hand, in order to explain the differences in the clinical response to CBZ, genetic polymorphisms in phase I (CYP3A4, CYP3A5 and EPHX1) and phase II (UGT2B7) metabolising enzymes have been assessed; additionally, the influence of transporters (ABCB1 and ABCC2), receptors (PXR) and other drug targets (voltage- gated Na+ channels) in CBZ clinical response has been evaluated.